As expected, NAFLD mice treated with MERTK+/hi M2c macrophages significantly alleviated liver burden indexed by the reduction of inflammation and hepatic steatosis, even though hepatocytes ballooning was still present. Here, MERTK is linked to metabolic dysfunction-associated steatotic liver disease.